43 results about "Elimination" patented technology

The invention discloses a highly inert Gd-DOTA-based contrast agent with a hydrophobic side chain as well as a preparation method and application of the highly inert Gd-DOTA-based contrast agent, and two novel Gd-DOTA-based contrast agents Gd-L1 and Gd-L2 are successfully developed by respectively connecting hydrophobic 3-phenyl propylamine and 3, 3-diphenyl propylamine to Gd-DOTABA. The two novel Gd-DOTA-based contrast agents remarkably improve the chemical inertness of the complex, the dissociation half-life period of the complex in a 1 M HCl solution at 37 DEG C is about 5 times that of Gd-DOTA, and a powerful guarantee is provided for clinical safety; the MRI (Magnetic Resonance Imaging) performance of the liver in a mouse shows that Gd-L1 is equivalent to commercially available Gd-BOPTA and is suitable for imaging of a liver and gall system; after the Gd-L2 is combined with the human serum albumin, the longitudinal relaxation rate is obviously increased (r1 = 14.8 mM <-1 > s <-1 >, 1.4 T, 37 DEG C), the blood elimination half-life period in a rabbit model is about 18 minutes, and the Gd-L2 is suitable for vascular MRI (Magnetic Resonance Imaging). The two contrast agents avoid the spleen residual problem, the organ accumulation possibility is reduced, and a safer and more efficient MRI diagnostic tool is provided for clinic.

The invention relates to an HER2 (human epidermal growth factor receptor 2) targeting antibody coupling gold (III) porphyrin medicine as well as a synthesis method and tumor treatment application thereof. The antibody coupling gold (III) porphyrin drug targeting HER2 is formed by connecting an anti-HER-2 trastuzumab and an A3B type gold (III) porphyrin complex through a linker, and the linker comprises a maleimide joint connected with an antibody and a self-elimination joint connected with the A3B type gold (III) porphyrin complex. The A3B type gold (III) porphyrin complex with anti-tumor activity is combined with trastuzumab with a specific recognition function as a carrier, the antibody is utilized to accurately strike tumor cells, a medicine is delivered to a tumor environment, the tumor targeting property of the gold (III) porphyrin complex is improved, and accurate treatment is realized. Distribution of drugs in the body can be improved, accumulation of the drugs in non-tumor sites can be reduced, the dosage of metal complexes is reduced, and toxic and side effects are reduced; the efficient delivery of gold drugs to tumor tissues can also be realized, and the cancer treatment effect is improved.

A system and method for rendering a diseased organ implant eligible, the method including acquiring an image data set of a potential donor organ, identifying one or more disease states in the potential donor organ, wherein the one or more disease states render the organ ineligible for transplant, harvesting the potential donor organ, applying histotripsy therapy, and confirming elimination / reduction of the disease state in the potential donor organ.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The application discloses a slow-release micro-pellet containing gamma-aminobutyric acid and a preparation method and application thereof. Gamma-aminobutyric acid is wrapped in a mucosal adhesion material in a fluidized bed to form a micro-pellet, and the micro-pellet is dispersed in an aqueous alginate solution to form a micro-pellet with a size of about 1-10 mm through calcium ion cross-linking. The slow-release micro-pellet overcomes the shortcomings of a product without cross-linked alginate, such as poor slow-release effect and easy burst release of active ingredients, has a biological membrane adhesion property, can realize stable release of GABA in a small intestine for at least 8 hours, presents obvious slow-release characteristics in a beagle dog in vivo, significantly delays a peak time, significantly reduces a peak concentration, significantly prolongs an elimination half-life, keeps a blood drug concentration stable and small fluctuation, and significantly improves a relative oral bioavailability. The application has the advantages of a soft and elastic texture after water absorption, chewability, and flexible and various taking modes. In addition, the application has a simple preparation process and can realize industrial production.

This invention belongs to the field of bioengineering technology and discloses a method for specific targeting and scarless simultaneous elimination blue KPC‑2 Gene and IncL plasmid sgRNA sequences, CRISPR / Cas9 vector system and applications. This system targets the sgRNA of the IncL plasmid. blue KPC‑2 The IncL-type plasmid of the gene was designed with an sgRNA that specifically recognizes the conserved sequence at its origin of replication, thus eliminating the drug resistance gene while disrupting the plasmid's replication ability. Conjugation transfer to recipient bacteria significantly improved vector delivery efficiency. An arabinose-inducible promoter was used to control Cas9 gene expression, improving system stability and editing success rate. The vector carries a sucrose-inducible self-eliminating gene, enabling controlled vector self-elimination. This system is not a simple superposition but rather constitutes a time-controlled operational flow: efficient delivery via conjugation, controlled cleavage via induction, and finally, induced self-elimination.

The application discloses an ether bond connected linker-drug molecule and an antibody conjugated drug, a preparation method and application thereof, and particularly discloses a compound represented by formula (1) or (2), or a tautomer, a mesomer, a racemate, an enantiomer, a diastereomer or a mixture form thereof, or a pharmaceutically acceptable salt, a prodrug or a solvate thereof, a composition containing the same or a use thereof. The compound of the application is connected with a drug molecule through an ether bond through a polypeptide (VC, VA, AAA)-PAB (self-elimination group) on a linker, greatly enhances the drugability (including hydrophilicity and stability) of the compound to an antibody drug conjugate, reduces the drug clearance in the body, and improves the tumor treatment effect.

The present invention relates to a conjugate in which a camptothecin-based drug (e.g., epatan and dxd) of formula 1, which is designed so as to bind to a DDX5 protein, is linked to an acid-sensitive linker, and to a carrier-drug conjugate using the conjugate. The present invention relates to: a conjugate in which a camptothecin-based drug (e.g., epatan and dxd) of formula 1, which is designed so as to bind to a DDX5 protein, is linked to an acid-sensitive linker; the camptothecin-based drug of formula 1 designed in a manner of binding to DDX5 protein according to the present invention not only can bind to DDX5 protein in cells and induce cell death by degradation of DDX5 protein, but also can preferably solve the problem of aggregation of a carrier-drug conjugate together with an acid-sensitive linker when used as a payload. Furthermore, the carrier-drug conjugate according to the present invention, when linked to a camptothecin-based drug of formula 1 by an acid-sensitive linker, prevents phagocytosis by macrophages in in vivo administration, distribution and elimination pathways after in vivo injection, and, due to the phagocytosis of the macrophages on reticuloendothelial system organs, has a significant therapeutic effect on the reticuloendothelial system organs. The composition cannot be absorbed by liver, spleen, bone marrow or lymph nodes, and can provide desired blood circulation characteristics.

Treatment compositions and methods for treating and / or preventing actinic keratosis comprising applying a chlorin treatment composition in a topical form to one or more actinic keratosis lesions. A treatment composition preferably comprises a copper chlorin, such as a sodium copper chlorophyllin complex, trisodium copper chlorin p6, disodium copper isochlorin e4, or trisodium copper chlorin e6. A treatment composition comprises around 0.002% to around 0.1% by weight of copper chlorin. Treatments disclosed herein may result in elimination of the actinic keratosis lesions.

The invention discloses a combined medicine for preventing and treating chronic cervicitis and a preparation method thereof. The combined medicine comprises a scavenger I and a scavenger II, according to the combined medicine and the preparation method provided by the invention, comprehensive treatment is carried out by combining a mature therapy and an elimination therapy which are special for Uighur medicine, the vagina environment is changed, the local immune function is improved, and a treatment mode which is definite in curative effect, safe and low in price is provided for chronic cervicitis.

The application belongs to the field of biomedical engineering, and discloses a human live mucosa organoid and a construction method and application thereof. The construction of the organoid comprises the following steps: preparing a cell gel compound, filling the cell gel compound into a support, implanting the support into a nude mouse subcutaneously after gelation, and obtaining the human live mucosa organoid after culturing for 1-3 weeks. The application also discloses the application of the organoid in disease research or drug screening. The application constructs a sustainable in-vivo biomimetic air-mucosa gas-liquid interface, realizes the transition of mucosa from an "ex-vivo static model" to an "in-vivo dynamic live system", and realizes the comprehensive evaluation of the curative effect of anti-infection drugs from three dimensions of pathogenic bacteria elimination, inflammation reaction regulation and immune cell recruitment inhibition in application, thereby breaking through the limitation of traditional models that can only evaluate the in-vitro bacteriostatic activity and being more consistent with the actual effect of clinical drug treatment.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, “treatment” generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The invention belongs to the technical field of toxicological evaluation, and discloses a photoresponsive liver chip system for evaluating drug immunotoxicity, which comprises a liver chip with a multilayer structure, a photoresponsive immune cell elimination reagent and an illumination device. The invention also discloses an application of the photoresponsive liver chip system in drug immunotoxicity evaluation, which comprises the following steps: firstly, in a state that the photoresponsive immune cell elimination reagent is not activated, performing a first round of toxicity detection on a to-be-detected drug to obtain baseline toxicity data; then, activating a reagent through illumination, and specifically eliminating immune cells in the chip; then carrying out a second round of toxicity detection; the immunotoxicity contribution of the to-be-detected medicine is accurately evaluated by comparing the difference of two rounds of toxicity detection data. The method realizes sequential resolution evaluation on the direct toxicity and the immune-mediated toxicity of the drug on the same biological sample, overcomes the defects that a traditional method is tedious in operation and cannot distinguish toxicity sources, and has the advantages of rapidness, accuracy and high throughput.

The present invention relates to the field of microorganisms, and in particular to a strain of Bacillus amyloliquefaciens and its application. The Bacillus amyloliquefaciens is named Bacillus amyloliquefaciens ( Bacillus amylolyticus )Wang, and was deposited in the China Center for Type Culture Collection on May 20, 2024, with the deposit number CCTCC NO:M 20241004. The Bacillus amyloliquefaciens described in the present invention can degrade copper ions in the environment, and also has a biological elimination effect on copper ions. It can reduce the accumulation of copper in the body by promoting the expression of ATP7A gene and ATP7B gene, reduce copper absorption by inhibiting the expression of copper transporter gene SLC31A1, and reduce oxidative stress by upregulating the expression of antioxidant genes SOD1 and SOD3. In addition, the Bacillus amyloliquefaciens described in the present invention has a protective effect on visceral organs, which is manifested in reducing the activity of enzymes (alanine aminotransferase, γ-glutamyl transferase, alkaline phosphatase) in visceral organs, especially liver organs, and reducing visceral organ stress response and damage.

The invention provides a method for early elimination of chickens with abnormal invisible tissues or pathological changes, which comprises the following steps: S1, determining detection indexes, laying the chickens on an experiment table with the backs facing downwards, removing feathers at action sites, and uniformly smearing a coupling agent; the detection indexes comprise liver, abdominal cavity, and / or ovary, and / or fallopian tube; s2, setting detection parameters of a Doppler diasonograph, and detecting the chicken by using a probe; and S3, observing in the inspection process, storing and recording a corresponding detection result, and eliminating the chicken with abnormal invisible tissues or pathological changes according to the detection result. The method provided by the invention can diagnose the abnormality or lesion of the liver, abdominal cavity, ovary and fallopian tube of the chicken in different breeding periods, can timely discover the hidden abnormality and no obvious disease symptom and behavior characteristics of the chicken, and screens out and eliminates the abnormal abnormality and no obvious disease symptom and behavior characteristics, thereby effectively reducing the breeding cost, improving the breeding benefit, and improving the economic benefit of the chicken. And unnecessary breeding economic loss is avoided.

A compound, or a salt or solvate thereof, according to formula (I) as defined herein and pharmaceutical composition comprising said compound. Compounds of formula (I) are capable of the selective elimination of senescent cells in a subject or biological sample. As such, these senolytic compounds can be useful in treatment of a disease or condition mediated by senescence.

The application discloses an intestinal microbial marker combination for cirrhosis diagnosis and application thereof, which is composed of 8 specific intestinal bacterial species. The application accurately identifies the core combination from 181 differential characteristics by performing metagenomic sequencing on fecal samples of cirrhosis patients and healthy controls, and combining random forest, LASSO regression and recursive feature elimination algorithms. The random forest diagnosis model based on the 8 markers realizes an excellent performance of area under curve (AUC) 0.841, sensitivity 84.3% and specificity 83.7% on a completely independent test set, and the performance does not decrease compared with the full feature model in the case of reducing the number of characteristics by 86.9%. The marker combination provided by the application is highly simplified and has strong discrimination, and provides a clear and efficient microbiological basis and technical scheme for developing a cirrhosis non-invasive diagnosis kit, a gene chip and other products based on intestinal flora.

The invention relates to the field of cancer treatment, and particularly discloses a synthetic method and application of a dual-response bimetallic nano-catalyst, and the synthetic method comprises the following steps: 1, synthesizing CuFeMOF nanoparticles; (2) synthesizing CuFeMOF (at) GOx nano particles; step 3, synthesizing a CuFeMOF (at) GOx (at) Mem) nano particle structure catalyst; under the action of an erythrocyte membrane, after the CuFeMOF (at) GOx (at) Mem is accumulated in a tumor tissue, GOx catalyzes glucose to generate H2O2 and gluconic acid, the gluconic acid aggravates reduction of PH in the tissue, the CuFeMOF (at) GOx (at) Mem is further activated to release Fe < 3 + > and Cu < 2 + >, then the Fe < 3 + > and the Cu < 2 + > are converted into Fe < 2 + > and Cu < + > by GSH, and Fe < 2 + >-mediated Fenton reaction is activated; in addition, Cu < + > can further promote conversion from Fe < 3 + > to Fe < 2 + >, and the CDT (chemodynamic therapy) effect is enhanced. The capacity of continuously accumulating Fe < 2 + > and eliminating GSH is shown through the amplification effect among GSH, Fe and Cu ions. In conclusion, according to the nano system, the effect of the CDT is greatly improved through a triple regulation mechanism of H2O2 self-supply, catalyst self-circulation and GSH self-elimination, and a unique method is provided for improving the anti-tumor potential of the CDT.

Traditional CYP2E1 activity detection adopts an elimination phase 6-hydroxy chlorzoxazone and chlorzoxazone ratio, but is interfered by UGT enzyme elimination, so that activity evaluation is distorted, and the CYP2E1 metabolism generation capability cannot be truly reflected. The invention discloses a simple method, system and kit for characterizing CYP2E1 activity. The method comprises the following steps: a, obtaining a biological sample after chlorzoxazone is administered; b, determining the concentration ratio of 6-hydroxy chlorzoxazone to chlorzoxazone of the sample at the highest time point of the absorption phase; the highest time point of the absorption phase is the peak reaching time of the concentration of 6-hydroxychlorzoxazone. It is found that after chlorzoxazone is applied to an organism, blood should be taken from the absorption phase of chlorzoxazone, and the activity of CYP2E1 can be really reflected.

The present disclosure provides recombinantly manufactured fusion proteins comprising a HERV-K (HML-2) Env protein fragment or an analog thereof linked to a human Fc fragment. Embodiments include the administration of the fusion proteins to patients having a disease or a disorder with the intention of mitigating and / or reducing the duration of symptoms associated with the condition or disease (for example but not limited to muscular weakness, paralysis and respiratory failure), and / or preventing symptoms associated with the condition or disease, for example, by preventing motor neuron degeneration and cell death in ALS patients associated with the condition or disease. Accordingly, "treatment" generally means both therapeutic treatment and prophylactic or preventative measures. Improvement after treatment may be manifested as a decrease or elimination of such symptoms, e.g., by a decrease or elimination of symptoms associated with ALS, and / or by a decrease in the duration of such symptoms.

The present invention belongs to the field of medical detection and intelligent diagnosis and treatment technology, and specifically relates to a leg thrombosis detection and evaluation method, system and storage medium. The system integrates a main control device and a blood flow velocity detection device, a vascular ultrasound detection device, a hemodynamic detection device, a blood sample collection and analysis device, a risk level assessment device and a corresponding strategy generation device. Through the integration of the above devices, progressive risk level determination can be achieved. The thrombosis risk level is first determined through preliminary physical testing, and corresponding risk elimination strategies are formulated for different risk levels. Biochemical testing is performed on high-risk patients with third-level thrombosis risk, and the pathological pathogen and specific type of thrombosis are determined in combination with the patient's clinical symptoms and signs to generate a treatment plan. The thrombosis monitoring and judgment method process combines the advantages of physical methods and biochemical methods, which not only ensures the accuracy and scientific nature of the detection, but also reduces the patient's pain and medical burden.

The present disclosure relates to the compound of an elastase inhibitor having the structure of Formula (I), the crystal form of the said inhibitor and its preparation method, the amorphous form of the said inhibitor and its preparation method and applications of these. The preparation method in present disclosure has advantages in simplicity, good repeatability, strong drug induction ability, high in-vivo exposure, long pharmacokinetic elimination half-life and high safety. The crystal form or amorphous form of present compound has beneficial effects such as high solubility and good stability. The preparation methods for the crystal form or amorphous form of the present compound are simple, easy to control and have a good reproducibility in the crystallization process.

The present invention includes a method of detecting and treating a patient suspected of having Barrett's esophagus comprising: obtaining a biological sample from an esophagus of the patient; determining a microbiome in the biological sample by detecting the presence of bacteria by plasmid dilution verification or quantitative polymerase chain reaction (qPCR); wherein if the patient has a microbiome indicative of an increased risk of esophageal cancer threating the patient with at least one of: removing at least part of the esophagus, esophagectomy probiotic therapy, or chemically targeting elimination of bacteria indicative of an increased risk of esophageal cancer.

The application provides a hydroxyl-substituted beraprost derivative, a synthesis method and application thereof, and belongs to the technical field of drugs.The compound is a coupling compound containing beraprost and a nitric oxide donor.The compound solves the defects of short elimination half-life of beraprost sodium, multiple single-day administration, saturation ceiling effect of curative effect, short metabolic half-life of NO which is a gas and is rapidly decomposed in a solution, and the like, the new compound reduces the original beraprost administration dose and administration frequency, and simultaneously utilizes the relaxation of smooth muscle caused by the release of NO molecules in the body of the compound, so that the two drugs play a synergistic effect through double action, and the effectiveness and safety of the drug are improved.

The present disclosure relates to a targeted elimination and / or clearance of target macromolecules. More specifically, the present disclosure provides bifunctional targeted elimination compounds designed to specifically recognize, bind, optionally neutralize, and direct target macromolecules toward degradation and / or clearance organs. The targeted elimination compound comprises at least one target-recognition component, which selectively binds to and optionally neutralizes a target macromolecule, and at least one elimination and / or clearance-targeting component, which directs the bound macromolecule to a degradation and / or clearance organ in a eukaryotic organism. These compounds, as well as associated methods and therapeutic applications, are disclosed herein.

Treatment compositions and methods for treating and / or preventing actinic keratosis comprising applying a chlorin treatment composition in a topical form to one or more actinic keratosis lesions. A treatment composition preferably comprises a copper chlorin, such as a sodium copper chlorophyllin complex, trisodium copper chlorin p6, disodium copper isochlorin e4, or trisodium copper chlorin e6. A treatment composition comprises around 0.002% to around 0.1% by weight of copper chlorin. Treatments disclosed herein may result in elimination of the actinic keratosis lesions.

The invention discloses a paclitaxel derivative. The paclitaxel derivative is a compound as shown in a molecular formula 6. The invention also claims to protect a preparation method and application of the paclitaxel derivative, and an antitumor drug containing the paclitaxel derivative. The paclitaxel derivative provided by the invention can reduce the distribution of drugs to non-target tissues and organs, accelerate the in-vivo elimination process of the drugs, reduce the residence time of the drugs in blood, and reduce toxic and side effects such as blood toxicity and neurotoxicity of the drugs.

The objective is to obtain a biological elimination device that can prevent the target organism from becoming accustomed to a specific elimination method, depending on the number of times the target organism has invaded. [Solution] The system includes: an acquisition unit 7 that acquires detection information indicating that an organism to be eliminated 3 has entered the monitoring area 12 from a detection unit 5 that detects when an organism to be eliminated 3 has entered the monitoring area 12; and a control unit 11a that controls the elimination execution unit 6, which performs elimination to prevent the organism to be eliminated 3 from entering an intrusion-prohibited area, to change the elimination means executed by the elimination execution unit 6 to a different elimination means than the one executed when the cumulative number of eliminations was less than the predetermined number, if the cumulative number of eliminations, which is the number of times the organism to be eliminated 3 has entered the monitoring area 12, is greater than or equal to a predetermined number, based on the detection information.